Medical/Pharmaceuticals
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- The University of Texas MD
Anderson Cancer Center
2022-09-14 11:09
1944
New Study by Lunit and MGH Validates Effectiveness of AI as Aid in Chest X-Ray Interpretation - Published in JAMA Network Open
* Joint study with Massachusetts General Hospital proves that Lunit's
AI-powered chest x-ray analysis software enhances the overall performance and
efficiency of radiologists SEOUL, South Korea, Sept. 13, 2022 /PRNewswire/ -- A
recent study published in
2022-09-13 22:16
2155
EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"
* An expert from Invitae and Ambry Genetics, U.S. genome analysis companies * EDGC states, "We will expand the overseas genome analysis market and advance into the global liquid biopsy technology market by recruiting a global talent in the genome field" * Worked in a non-profit research orga...
2022-09-13 21:00
2274
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (...
2022-09-13 20:00
2826
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster featuring its F...
2022-09-13 14:02
1969
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
This Blood-based Multi-Cancer Early Detection Test Combines Protein Tumor Markers And Artificial Intelligence SHENZHEN, China, Sept. 12, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark appr...
2022-09-12 21:37
1915
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
* Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients * For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40% * Lemzoparlimab does not require priming ...
2022-09-10 21:00
2725
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- Redbud Medicine, the Delaware -headquartered contract research organization (CRO) announced on Monday following the completion of a series A round fundraising in which MING Bioventures Capital, Delian Capital and the existing Angel round investor Hongfeng C...
2022-09-10 05:13
2448
WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection dosag...
2022-09-09 20:00
2940
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, today announced that its Board of Directors (the "Board") has received an unsolicited preliminary non-binding proposal letter (the "Proposal") dated...
2022-09-09 17:53
2699
Antengene to Present at Upcoming Industry Conferences
SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...
2022-09-09 14:43
2327
Pulnovo Medical Concludes Successfully the First Steering Committee Meeting
SHANGHAI, Sept. 8, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally
recognized OTM innovative platform, today announced that it has successfully
concluded the first Steering Committee meeting for PADN Global Clinical Trial.
2022-09-08 20:30
2180
InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer
NANJING, China, Sept. 7, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study ...
2022-09-08 08:00
2251
Biosion, Inc. Appoints Dr. Rakesh Dixit, ADC Thought Leader, to Advisory Board
NEWARK, Del., Sept. 7, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global R&D biotechnology company, today announced the appointment ofRakesh Dixit , Ph.D., DABT to its Advisory Board to advance Antibody Drug-Conjugates (ADCs) for the treatment of solid tumor cancers in Biosion's pipeline. ...
2022-09-07 20:54
3551
Lianhua Products Designated as Epidemic Prevention Supplies : 2022 CIFTIS
SHIJIAZHUANG, China, Sept. 7, 2022 /PRNewswire/ -- The 2022 China International Fair for Trade in Services (CIFTIS), which opened onAugust 31, 2022, in Beijing , is the only annual international and comprehensive platform for trade in services in the world. Yiling Pharmaceutical's Lianhua respirat...
2022-09-07 20:15
4057
GenFleet Therapeutics to Present Data from Phase I Trial of GFH018 Monotherapy at the 2022 European Society for Medical Oncology Annual Meeting
SHANGHAI and PARIS, Sept. 7, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH018 (TGF-β R1 inhibitor) monotherapy (NCT05051241) for treatment of a...
2022-09-07 19:00
3409
Laekna Announces First Patient Dosed in South Korea in LAE201INT2101 Phase 1/2 Study
SHANGHAI and WARREN, N.J., Sept. 6, 2022 /PRNewswire/ -- Laekna, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver fibrosis patients worldwide, announced yesterday that the first patient recently received a dose in the LAE201INT2101 phase ...
2022-09-06 17:02
2549
Amcor reveals Lift-Off seed capital winners with investments that seek to "drive the revolution in packaging"
Global packaging leader to provide US $250,000 to two start-ups with cutting edge innovations for a more sustainable future for packaging ZURICH, Sept. 6, 2022 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global leader in developing and producing responsible packaging solutions, has announced...
2022-09-06 16:10
3989
Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China
BEIJING, SHANGHAI and BOSTON, Sept. 6, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) has received Phase II pivotal study approval of KRAS G12C inhibitor JAB-21822 from the Center for Drug Evaluation (CDE) ofChina in September 5, 2022 . This study aims to treat advanced or metastatic non-small cell...
2022-09-06 15:20
2528
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO
* The confirmed objective response (cORR), as assessed by blinded independent central review (BICR), was 59.8% in advanced NSCLC with EGFR exon20ins mutations after at least one line of platinum-based chemotherapies * The response rate for patients with baseline brain metastasis was 48.4% * ...
2022-09-05 22:49
3558
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
59273
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
54297
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
52334
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
21776
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
17092